Brian Bergmark, MD
Cardiovascular Disease · Boston, MANPI 1750676375
Payments from drug & device makers
Across 454 payments — averaging $18,204 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7.6M
- Abbott$294K
- Spectrawave, Inc$106K
- Pfizer$63K
- Shockwave Medical, Inc$62K
- Cardiovascular Systems Inc.$57K
- plus $109K from 10 others
Across 1 payment — averaging $3200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$3K
What the payments were for
- Consulting fees$205,37571%
- Speaking & faculty fees$57,59020%
- Travel & lodging$15,6355%
- Food & beverage$12,0934%
- Education$1920%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $7,573,917 |
| Abbott | 201 | $293,706 |
| Spectrawave, Inc | 12 | $106,440 |
| Pfizer | 2 | $63,304 |
| Shockwave Medical, Inc | 48 | $61,969 |
| Cardiovascular Systems Inc. | 45 | $56,607 |
| Inari Medical, Inc. | 30 | $38,631 |
| Teleflex LLC | 18 | $20,948 |
| Abiomed | 19 | $18,108 |
| Boston Scientific | 20 | $18,045 |
| Philips North America LLC | 15 | $7,915 |
| Magenta Medical Inc | 3 | $4,107 |
| Terumo Medical Corporation | 2 | $700 |
| Stryker | 2 | $39 |
| Heartflow, Inc. | 1 | $23 |
| Astrazeneca UK Limited | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$107,094
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$61,309
- Xience V coronary stent system$29,623
- Impella$18,008
- HI-TORQUE BALANCE$13,250
- GUIDELINER V3 CATHETER$9,900
- TURNPIKE$9,725
- Vitalyst$5,173
- HyperVue Imaging System$4,500
- Starlight Imaging Catheter$4,000
- GENERAL VASCULAR ACCESS$2,500
- Diamondback Coronary$2,171
- Dragonfly OCT$1,500
- Ultreon$1,500
- GUIDELINER$960
- SUPERA$711
- Optis Coronary Imaging System$554
- XIENCE SIERRA$447
- Optitorque$350
- Peripheral Orbital Atherectomy System$314
How this compares
$8,264,472 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ranolazine ErRanolazine | 18 | $3,201 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 17 | $923 |
| Metoprolol Succinate | 25 | $889 |
| Rosuvastatin Calcium | 21 | $778 |
| Ezetimibe | 18 | $684 |
| Atorvastatin Calcium | 22 | $388 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$31.2M
- Stephen WiviottBoston$29.2M
- David MorrowBoston$19M
- Scott SolomonBoston$16.2M
- Paul RidkerBoston$16.2M
- Mohit JainBoston$13M
- Calum MacraeBoston$11.4M
- Benjamin SciricaBoston$11.3M
- Robert GiuglianoBoston$10.5M
- Erin BohulaBoston$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.